PRKG2 antibody (C-Term)

Catalog No. ABIN392537

There are 4+ publications for this product available. The Rabbit Polyclonal anti-PRKG2 antibody is suitable to detect PRKG2 in samples from Human. It has been validated for WB and IHC (p).

Quick Overview for PRKG2 antibody (C-Term) (ABIN392537)

Target: PRKG2 (Protein Kinase, CGMP-Dependent, Type II (PRKG2))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PRKG2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB01036

Product Details anti-PRKG2 Antibody

Binding Specificity: AA 714-744, C-Term

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This cGKII antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 714-744 amino acids from the C-terminal region of human cGKII.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. IHC-P: 1:50~100. IHC-P: 1:50~100

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

References for anti-PRKG2 antibody (ABIN392537)

Zhu, Yao, Wu, Qian, Wu, Chen: "Type II cGMP-dependent protein kinase directly inhibits HER2 activation of gastric cancer cells." in: Molecular medicine reports, Vol. 13, Issue 2, pp. 1909-13, (2016) (PubMed).

Yao, Wu, Zhu, Qian, Chen et al.: "Nitric oxide/cyclic guanosine monophosphate inducers sodium nitroprusside and L-arginine inhibit the proliferation of gastric cancer cells via the activation of type II cyclic guanosine ..." in: Oncology letters, Vol. 10, Issue 1, pp. 479-484, (2015) (PubMed).

Jiang, Wu, Wu, Lan, Wang, Qian, Chen: "Type II cyclic guanosine monophosphate-dependent protein kinase inhibits epidermal growth factor receptor activation in different cancer cell lines." in: Oncology letters, Vol. 9, Issue 6, pp. 2781-2786, (2015) (PubMed).

Rangaswami, Marathe, Zhuang, Chen, Yeh, Frangos, Boss, Pilz: "Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction." in: The Journal of biological chemistry, Vol. 284, Issue 22, pp. 14796-808, (2009) (PubMed).

Target Details for PRKG2

Target: PRKG2 (Protein Kinase, CGMP-Dependent, Type II (PRKG2))

Alternative Name: cGKII

Background: CGKII is thought to play a key role in a diverse set of physiological pathway. cGKII may mediate intestinal secretion of water and electrolytes induced by the E. coli toxin STa and the intestinal peptide guanylin. Edentification of the pathway that mediates intestinal fluid secretion by E. coli STa has potential medical implications because STa causes traveler's diarrhea and about 50 % of infant mortality in developing countries. Transfection experiments in human cells disclose that cGKII phosphorylates SOX9 and attenuates SOX9 function by inhibiting its nuclear entry. Impaired differentiation of cultured KMI chondrocytes can be restored by silencing Sox9 by RNA interference. cGKII is postulated to be a molecular switch that couples the cessation of proliferation and the start of hypertrophic chondrocyte differentiation through attenuating SOX9 function.

Molecular Weight: 87432

Gene ID: 5593

NCBI Accession: NP_006250

UniProt: Q13237